Edge Therapeutics, Inc. Uncategorized Contracts & Agreements
13 Contracts & Agreements
- Amendment to the Eighth Amended and Restated Certificate of Incorporation (Filed With SEC on June 24, 2024)
- Executive Employment Agreement by and between Stephan F. Toutain and PDS Biotechnology Corporation, effective as of May 1, 2024 (Filed With SEC on May 15, 2024)
- PDS Biotechnology Corporation 2019 Inducement Plan, as amended (Filed With SEC on January 22, 2024)
- PDS Biotechnology Corporation 2019 Inducement Plan, as amended (Filed With SEC on May 18, 2022)
- Option Agreement with University of Georgia Research Foundation, Inc. effective as of October 25, 2021 (Filed With SEC on March 31, 2022)
- PDS Biotechnology Corporation 2019 Inducement Plan, as amended (Filed With SEC on December 9, 2020)
- Description of Securities (Filed With SEC on March 27, 2020)
- Offer Letter, dated February 1, 2019, by and between PDS Biotechnology Corporation and Lauren V. Wood, M.D (Filed With SEC on August 1, 2019)
- PDS Biotechnology Corporation 2019 Inducement Plan (Filed With SEC on June 20, 2019)
- Letter Agreement, dated as of February 3, 2019, by and among Edge Therapeutics, Inc., PDS Biotechnology Corporation and Brian A. Leuthner (Filed With SEC on February 4, 2019)
- Offer Letter, dated September 21, 2018, by and between PDS Biotechnology Corporation and Lauren Wood, MD (Filed With SEC on December 21, 2018)
- EXECUTIVEEMPLOYMENT AGREEMENT (Filed With SEC on November 5, 2015)
- AMENDMENT TO THEedge therapeutics, inc. 2010 EQUITYINCENTIVE Plan (Filed With SEC on August 14, 2015)
